• BioVaxys (BIOV) has acquired TAETSoftware, a Vancouver-based clinical studies management company
  • TAETSoftware is developing a software application for clinical study subjects to record and submit Adverse Drug Events reports to study sponsors in real time
  • Consideration includes 24,500,000 common shares, with an additional 2,500,000 common shares payable upon the successful testing of the application’s beta version
  • CEO James Passin joined Coreena Robertson to discuss the news
  • Additionally, BioVaxys closed a private placement consisting of 5,360,000 common shares priced at $0.125 for gross proceeds of $670,000
  • Vancouver-based BioVaxys is a clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics
  • BioVaxys Technology (BIOV) opened unchanged trading at $0.07 per share

BioVaxys (BIOV) has acquired TAETSoftware, a Vancouver-based clinical studies management company.

TAETSoftware is developing its Trial Adverse Events Tracker technology platform, a proprietary software application for clinical study subjects to record and submit Adverse Drug Events (ADEs) reports to study sponsors in real time.

The solution is a step up in efficiency from paper-based reporting, which is limited by under-reporting, poorly documented reporting and reporting delays.

Consideration includes 24,500,000 common shares, with an additional 2,500,000 common shares payable upon the successful testing of the application’s beta version.

BioVaxys is evaluating the potential to offer blinded demographic and disease data to companies interested in healthcare analytics and data mining.

CEO James Passin joined Coreena Robertson to discuss the news.

Additionally, BioVaxys has closed a private placement consisting of 5,360,000 common shares priced at $0.125 for gross proceeds of $670,000. All issued shares are subject to a statutory hold period of four months and one day. The company intends to use the proceeds for working capital.

Vancouver-based BioVaxys is a clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

BioVaxys Technology (BIOV) opened unchanged trading at $0.07 per share.


More From The Market Online

Revolutionizing medical imaging with nanocarbon-based contrast drugs

The partnership between Rain Cage Carbon and Voyageur Pharmaceuticals (TSXV:VM) is transforming carbon capture and reuse technology.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.

Theralase enhances cancer drug efficacy

Theralase Technologies (TSXV:TLT) announces its Ruvidar compound creates a new compound able to significantly kill more cancer cells.

FDA committee rejects MDMA drug, discounting psychedelic stocks

A committee of the U.S. FDA rejects a drug application to treat PTSD using MDMA-assisted therapy, causing numerous stocks to fall.